Every Form 4 that Champions Oncology, Inc. (CSBR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CSBR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CSBR filings page.
Champions Oncology, Inc. (CSBR) director Joel Ackerman exercised options covering 69,794 shares of common stock on October 15, 2026, at an exercise price of $1.60 per share. The transaction reported acquisition of 69,794 common shares, bringing his directly held common-stock position to 1,126,333 shares; the option position was reported as 0 following the exercise.
Champions Oncology (CSBR) CEO and director Robert L. Brainin received several option grants to buy common stock at an exercise price of $7.80 per share on July 16, 2025, expiring on July 16, 2035.
The awards include time-based vesting, where 25% vests on July 16, 2026 and the rest monthly over three years, plus multiple performance-based tranches. These performance options vest only if the company reaches EBITDA of $25 million or $35 million over any four-quarter period, achieves data revenue of $15 million or $30 million over any four-quarter period, or maintains a 45‑day average stock price at or above strike prices of $16.00 and $24.00.
Champions Oncology director Robert Lawrence Brainin reported multiple stock option awards over several years. The Form 4 shows options to purchase common stock granted on November 5, 2021, November 1, 2022, November 3, 2023, and November 12, 2024, at exercise prices of $10.10, $7.00, $5.51, and $4.64 per share, respectively.
Each grant vests over twelve months in four installments on specified quarterly dates. After the most recent November 12, 2024 award of 23,030 options, Brainin beneficially owned 74,163 stock options directly, all expiring ten years from their respective grant dates.
Champions Oncology (CSBR) reported a Form 4 showing a director was granted an option to purchase 13,790 shares of common stock on November 5, 2025 at an exercise price of $6.8 per share. The option has a ten-year term expiring on November 5, 2035.
The award vests over twelve months in four tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026. Following the grant, the reporting person holds 13,790 derivative securities directly.
Champions Oncology (CSBR) reported an insider equity grant on a Form 4. Director David Sidransky was awarded an option to purchase 21,216 shares on 11/05/2025 at an exercise price of $6.8 per share, expiring on 11/05/2035.
The filing lists the transaction code as A (grant). The option was acquired in direct ownership. Vesting is scheduled over twelve months, with tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026. The option is exercisable over a ten‑year period.
Champions Oncology (CSBR) reported a director’s equity grant on a Form 4. The reporting person acquired an option to purchase 13,790 shares of common stock on 11/05/2025 at an exercise price of $6.80 per share. The option expires 11/05/2035 and vests over twelve months in four tranches on 11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026. Ownership is listed as Direct. This filing reflects routine director equity compensation and does not indicate cash proceeds to the company.
Champions Oncology (CSBR) insider activity: a director and 10% owner reported an award of derivative securities. On 11/05/2025, the reporting person acquired an option to purchase 25,460 shares of common stock at an exercise price of $6.80 per share, recorded as a Code A grant and held directly.
The options vest over twelve months in four dates—11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026—and are exercisable over ten years, with an expiration date of 11/05/2035.
Champions Oncology (CSBR) director reported a stock option grant. On 11/05/2025, the reporting person received 21,216 options to purchase common stock at an exercise price of $6.80 per share, with an expiration date of 11/05/2035.
The options vest over twelve months in four equal installments on Nov 5, 2025, Feb 5, 2026, May 5, 2026, and Aug 5, 2026. Following the transaction, 21,216 derivative securities were beneficially owned, reported as Direct (D) ownership.
Champions Oncology (CSBR) director Joel Ackerman reported an insider transaction on Form 4. On 10/30/2025, he exercised stock options for 94,405 shares at $2.1 per share (transaction code M), acquiring the same number of common shares.
After the transaction, he reported 1,056,539 shares beneficially owned directly and 0 derivative securities remaining. The exercised option covered 94,405 underlying shares with a $2.1 exercise price.